111 related articles for article (PubMed ID: 38457819)
1. Cost sharing for oral lenvatinib among commercially insured patients.
Liang MI; Chen L; Aviki EM; Wright JD
Am J Manag Care; 2024 Mar; 30(3):114-117. PubMed ID: 38457819
[TBL] [Abstract][Full Text] [Related]
2. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Liang MI; Chen L; Hershman DL; Hillyer GC; Huh WK; Guyton A; Wright JD
Gynecol Oncol; 2021 Mar; 160(3):793-799. PubMed ID: 33375989
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
4. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
6. How Have Patient Out-of-pocket Costs for Common Outpatient Orthopaedic Foot and Ankle Surgical Procedures Changed Over Time? A Retrospective Study From 2010 to 2020.
Goldfarb SI; Xu AL; Gupta A; Mun F; Durand WM; Gonzalez TA; Aiyer AA
Clin Orthop Relat Res; 2024 Feb; 482(2):313-322. PubMed ID: 37498201
[TBL] [Abstract][Full Text] [Related]
7. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
8. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
[TBL] [Abstract][Full Text] [Related]
9. Patient cost sharing during poly(adenosine diphosphate-ribose) polymerase inhibitor treatment in ovarian cancer.
Harrison RF; Fu S; Sun CC; Zhao H; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2021 Jul; 225(1):68.e1-68.e11. PubMed ID: 33549538
[TBL] [Abstract][Full Text] [Related]
10. Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
Ingham M; Sadik K; Zhao X; Song J; Fendrick AM
J Manag Care Spec Pharm; 2023 Sep; 29(9):1084-1092. PubMed ID: 37548953
[No Abstract] [Full Text] [Related]
11. Correlation Between Changes in Brand-Name Drug Prices and Patient Out-of-Pocket Costs.
Rome BN; Feldman WB; Desai RJ; Kesselheim AS
JAMA Netw Open; 2021 May; 4(5):e218816. PubMed ID: 33944925
[TBL] [Abstract][Full Text] [Related]
12. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
Johnson JT; Neill KK; Davis DA
J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
[TBL] [Abstract][Full Text] [Related]
13. Out-of-Pocket Costs for Patients Undergoing Thyroid Surgery.
Zheng F; Huang Y; Wright J; Kuo JH
Ann Surg; 2022 Dec; 276(6):e937-e943. PubMed ID: 34261887
[TBL] [Abstract][Full Text] [Related]
14. Cost sharing, postpartum contraceptive use, and short interpregnancy interval rates among commercially insured women.
Moniz MH; Peahl AF; Fendrick AM; Kolenic GE; Tilea A; Wetmore M; Dalton VK
Am J Obstet Gynecol; 2021 Mar; 224(3):282.e1-282.e17. PubMed ID: 32898503
[TBL] [Abstract][Full Text] [Related]
15. Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes.
Fitch K; Pyenson BS; Iwasaki K
J Manag Care Pharm; 2013 Oct; 19(8):609-20, 620a-620d. PubMed ID: 24074007
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy costs with commercial insurance.
Rahman M; Chen L; Daw J; Wright JD; D'Alton ME; Wen T; Friedman AM
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):10143-10151. PubMed ID: 36104042
[TBL] [Abstract][Full Text] [Related]
17. The Economic Burden of Out-of-Pocket Expenses for Plastic Surgery Procedures.
Billig JI; Chen JS; Lu YT; Chung KC; Sears ED
Plast Reconstr Surg; 2020 Jun; 145(6):1541-1551. PubMed ID: 32459783
[TBL] [Abstract][Full Text] [Related]
18. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
19. Employer drug benefit plans and spending on prescription drugs.
Joyce GF; Escarce JJ; Solomon MD; Goldman DP
JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
[TBL] [Abstract][Full Text] [Related]
20. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
